Irinotecan Hydrochloride Accord Healthcare Ireland

Irinotecan Hydrochloride, the active ingredient in Irinotecan Hydrochloride Accord Healthcare Ireland, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It treats colorectal cancer, including metastatic disease, in adult patients.

GNH USA supplies Irinotecan Hydrochloride Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, pharmacies and clinics worldwide.

Irinotecan Hydrochloride is used in the management of colorectal cancer and related disease pathways.

- Colorectal cancer: improves survival by targeting rapidly dividing tumor cells. - Metastatic colorectal cancer: provides systemic therapy for advanced disease. - Advanced colorectal carcinoma: used as part of combination chemotherapy regimens to reduce tumor burden.

Irinotecan Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: often severe and may require antidiarrheal therapy. - Fatigue: general tiredness during treatment cycles. - Alopecia: hair loss that is usually reversible. - Neutropenia: reduced neutrophil count increasing infection risk. - Anemia: lowered red blood cell count causing fatigue.

Serious or Rare Side Effects: - Severe neutropenia: profound drop in neutrophils requiring medical intervention. - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Severe diarrhea (colitis): can lead to dehydration and electrolyte imbalance. - Liver enzyme elevation: indicates hepatic stress. - Allergic reactions: rash, itching, or anaphylaxis. - Pulmonary toxicity: rare lung inflammation.

When using Irinotecan Hydrochloride, clinicians should observe several precautionary measures to ensure patient safety.

- Assess baseline blood counts: obtain a complete blood count before each cycle. - Monitor liver function: check hepatic enzymes regularly. - Adjust dose in hepatic impairment: reduce dosage according to liver function tests. - Avoid concurrent strong CYP3A4 inhibitors: these may increase exposure. - Educate patients on early signs of diarrhea: prompt antidiarrheal therapy is essential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Hydrochloride interacts with several drugs that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase toxicity. - Concurrent use of other topoisomerase I inhibitors: additive bone marrow suppression. - High-dose aspirin or NSAIDs: increased risk of gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - UGT1A1 inhibitors (e.g., atazanavir): may raise plasma levels. - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Radiotherapy to abdomen: may enhance gastrointestinal toxicity.